Xigen

Xigen is a privately-owned biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) that specializes in the development of peptides for use against inflammation. Xigen's peptides have high stability and specificity. They are selectively delivered to their intracellular targets through proprietary carrier molecules. The company's lead compound, XG-102, is a D-amino-acids peptide, highly selective, non-competitive, long-acting inhibitor of c-jun N-terminal kinase (JNK). Xigen's second JNK inhibitor lead compound, namely XG-104, is a L/D-amino-acids peptide.